

**BME - GROWTH**

Palacio de la Bolsa  
Plaza de la Lealtad, 1  
28014 Madrid

Alicante, March 24<sup>th</sup> of 2022

**COMUNICACION- PRIVILEGED INFORMATION- FACEPHI BIOMETRIA, S.A.**

Dear Sirs,


Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 228 of the consolidated text of the Spanish Securities Market Law, approved by the Royal Legislative Decree 4/2015, of 23rd October, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

The Company published as privileged information on the 25th of January 2021 the resolutions adopted by the Extraordinary General Shareholders' Meeting held on that date, which included, as the first point, the delegation to the Board of Directors of the power to issue warrants convertible into shares of the Company in favour of Nice & Green, S.A. ("Nice & Green"), with the exclusion of pre-emptive subscription rights, for a maximum conversion amount of €20,000,000, as well as to increase de share capital by the amount necessary to cover the conversion of said warrants.

On 16th February 2022, the Board of Directors adopted a resolution, under the delegation of the Company's Extraordinary General Shareholders' Meeting of January 25th, 2021, to carry out the second issue of 48,076,923 warrants convertible into shares of the Company for a maximum conversion amount of €2,500,000 (the "Equity Warrants (FEBRUARY 2022)"), with Nice & Green being the sole subscriber of the issue of the Equity Warrants (FEBRERO 2022).

Nice&Green, on February 25<sup>TH</sup>, February 28<sup>TH</sup> and March 9<sup>TH</sup> of 2022, under the provisions of the investment agreement, notified to the Company and exercised its right to convert 32,290, 95,849 and 80,906 Equity Warrants (FEBRUARY 2022 ) for a joint conversion amount of 600,000 euros.

As a result of the foregoing, the Company has granted, on March 21<sup>st</sup> of 2022, a capital increase title deed to cover the conversion of that said Equity warrants issued. The new shares of the Company are issued, 32,290 shares with an issuing price of 3.0969 euros (issue premium 3.0569 euros plus 0.04 euros of nominal value); 95,849 shares with an issuing price of 3.1299 euros (3.0899 euros issue premium plus 0.04 euros nominal



value), and 80,906 shares with an issuing price 2.4720 euros (2.432 euros issue premium and 0.04 euros nominal value).

Following the aforementioned capital increase, the share capital is set at the sum of SIX HUNDRED THIRTEEN THOUSAND SEVEN HUNDRED AND THIRTY-FOUR EUROS AND SIXTY-EIGHT CENTS (€613,734.68), represented by FIFTEEN MILLION THREE HUNDRED AND FORTY-THREE THOUSAND THREE HUNDRED AND SIXTY-SEVEN (15,343,367) numbered from 1 to 15,343,367, shares of FOUR CENTS OF EURO (€0.04) nominal value each, of the same class, equal, cumulative and indivisible.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

-----

Javier Mira Miró

**Chairman of the Board of Directors**